Ghrelin -O -acyl transferase (GOAT) and their uses.

Developed by: Instituto de Investigación Biomédica de Córdoba (IMIBIC).


A Research Group from the Public Health System of Andalusia and the University of Cordoba has discovered biomarkers for the diagnosis of prostate cancer.


Presently, several biomarkers are used in clinical practice for the diagnosis of prostate cancer from non-invasive methods. Specifically, the most widely used is the PSA (prostate specific antigen), which has a sensitivity between 20 and 90 % depending on trim level and tumour grade.

In particular, it is to provide a diagnostic tool that serves as a clinically effective use of alternative PSA traditionally used and with a not very high cost. Researchers have found that by measuring expression levels of the GOAT (ghrelin -O -acyl transferase), can be used as a useful diagnostic tool in clinical practice, given its high specificity and sensitivity (66 % and 81 % respectively).

The use of biomarkers studied has the following advantages over the currently used methods for the diagnosis of prostate cancer:

- Minimally invasive methods.

- Good specificity and sensitivity.

- Moderate cost.

Estado de protección

This technology is protected by International Patent Application PCT. 

Desired cooperation

The research group is looking for a partner interested in a license and/or a collaboration agreement to further develop and exploit this innovative technology.

Health technology: